Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults
Malaria Journal, Volume 11, Article 132, Year 2012
Notification
URL copied to clipboard!
Description
Background: Severe malaria is a medical emergency with high mortality. Prompt achievement of therapeutic concentrations of highly effective anti-malarial drugs reduces the risk of death. The aim of this study was to assess the pharmacokinetics and pharmacodynamics of intravenous artesunate in Ugandan adults with severe malaria. Methods: Fourteen adults with severe falciparum malaria requiring parenteral therapy were treated with 2.4 mg/kg intravenous artesunate. Blood samples were collected after the initial dose and plasma concentrations of artesunate and dihydroartemisinin measured by solid-phase extraction and liquid chromatography-tandem mass spectrometry. The study was approved by the Makerere University Faculty of Medicine Research and Ethics Committee (Ref2010-015) and Uganda National Council of Science and Technology (HS605) and registered with ClinicalTrials.gov (NCT01122134). Results: All study participants achieved prompt resolution of symptoms and complete parasite clearance with median (range) parasite clearance time of 17 (824) hours. Median (range) maximal artesunate concentration (Cmax) was 3260 (1020164000) ng/mL, terminal elimination half-life (T was 0.25 (0.1-1.8) hours and total artesunate exposure (AUC) was 727 (290111256) ngh/mL. Median (range) dihydroartemisinin Cmax was 3140 (16709530) ng/mL, with Tmax of 0.14 (0.6 6.07) hours and Tof 1.31 (0.82.8) hours. Dihydroartemisinin AUC was 3492 (21836338) ngh/mL. None of the participants reported adverse events. Conclusions: Plasma concentrations of artesunate and dihydroartemisinin were achieved rapidly with rapid and complete symptom resolution and parasite clearance with no adverse events. © 2012 Byakika-Kibwika et al.
Authors & Co-Authors
Byakika-Kibwika, Pauline
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Lamorde, Mohammed
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Mayito, Jonathan
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Nabukeera, Lillian
Uganda, Kampala
Makerere University
Mayanja-Kizza, Harriet
Uganda, Kampala
Makerere University
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Katabira, Elly Tebasoboke
Uganda, Kampala
Makerere University
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Hanpithakpong, Warunee
Thailand, Nakhon Pathom
Mahidol University
Obua, Celestino
Uganda, Kampala
Makerere University College of Health Sciences
Pakker, Nadine G.
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Lindegårdh, Niklas
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Churchill Hospital
Tarning, Joel
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Churchill Hospital
de Vries, Peter J.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Merry, Concepta
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Statistics
Citations: 13
Authors: 13
Affiliations: 7
Identifiers
Doi:
10.1186/1475-2875-11-132
e-ISSN:
14752875
Research Areas
Health System And Policy
Infectious Diseases
Study Locations
Uganda